• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青少年起病的桥脑胶质瘤中的p53基因突变

p53 gene mutations in pontine gliomas of juvenile onset.

作者信息

Zhang S, Feng X, Koga H, Ichikawa T, Abe S, Kumanishi T

机构信息

Department of Neuropathology, Niigata University, Japan.

出版信息

Biochem Biophys Res Commun. 1993 Oct 29;196(2):851-7. doi: 10.1006/bbrc.1993.2327.

DOI:10.1006/bbrc.1993.2327
PMID:8240361
Abstract

Using polymerase chain reaction-single strand polymorphism(PCR-SSCP) and nucleotide analyses, p53 gene mutation was examined in 13 pontine gliomas many of which were of juvenile onset. A total of 15 mutations were detected in 8 cases, of which 5 revealed multiple or tandem mutations. The mutations included 6 G:C-A:T and 4 A:T-G:C transitions and 4 G:C-T:A and 1 A:T-T:A transversions. There was only 1 transition at the CpG site. Normal tissues of the same patients revealed no mutation, suggesting that these mutations were somatic, but not of germ line, in nature. The pattern of mutation characterized by frequent multiple or tandem occurrence, predominancy of transition at non-CpG sites and relatively frequent transversions suggested that pontine glioma might be related with some mutagenic or carcinogenic agents.

摘要

采用聚合酶链反应-单链多态性(PCR-SSCP)和核苷酸分析方法,对13例桥脑胶质瘤(其中许多为幼年发病)进行了p53基因突变检测。在8例病例中总共检测到15个突变,其中5例显示多个或串联突变。这些突变包括6个G:C-A:T和4个A:T-G:C转换以及4个G:C-T:A和1个A:T-T:A颠换。仅在CpG位点有1个转换。同一患者的正常组织未显示突变,表明这些突变本质上是体细胞突变,而非种系突变。以频繁出现多个或串联突变、非CpG位点转换占优势以及相对频繁的颠换为特征的突变模式表明,桥脑胶质瘤可能与某些诱变剂或致癌剂有关。

相似文献

1
p53 gene mutations in pontine gliomas of juvenile onset.青少年起病的桥脑胶质瘤中的p53基因突变
Biochem Biophys Res Commun. 1993 Oct 29;196(2):851-7. doi: 10.1006/bbrc.1993.2327.
2
[Mutations of p53 gene in 41 cases of human brain gliomas].41例人脑胶质瘤中p53基因的突变
Ai Zheng. 2008 Jan;27(1):8-11.
3
Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry.通过聚合酶链反应辅助单链构象多态性和免疫组织化学分析低级别和高级别星形细胞瘤中的p53基因突变。
Acta Neuropathol. 1994;87(3):225-32. doi: 10.1007/BF00296737.
4
Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.通过聚合酶链反应产物的单链构象多态性分析检测人脑肿瘤中的p53基因突变
Oncogene. 1991 Aug;6(8):1313-8.
5
Intracranial germ cell tumors: detection of p53 gene mutations by single-strand conformation polymorphism analysis.颅内生殖细胞肿瘤:通过单链构象多态性分析检测p53基因突变
Jpn J Cancer Res. 1995 Jun;86(6):555-61. doi: 10.1111/j.1349-7006.1995.tb02434.x.
6
p53 protein accumulation and gene mutations in human glioma cell lines.
Int J Cancer. 1993 Dec 2;55(6):982-7. doi: 10.1002/ijc.2910550618.
7
Alterations in tumour suppressor gene p53 in human gliomas from Indian patients.印度患者人脑胶质瘤中肿瘤抑制基因p53的改变
J Biosci. 2002 Dec;27(7):673-8. doi: 10.1007/BF02708375.
8
Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens.小儿脑干胶质瘤的分子遗传学。聚合酶链反应技术在小型及存档脑肿瘤标本中的应用。
J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15. doi: 10.1097/00005072-199309000-00009.
9
p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.人类恶性胶质瘤中的p53突变:杂合性缺失与突变频率的比较
Cancer Res. 1992 Mar 15;52(6):1427-33.
10
Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.多次活检患者星形细胞瘤进展过程中p53突变的发生率及时间
Clin Cancer Res. 1997 Apr;3(4):523-30.

引用本文的文献

1
H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.H3K27M、异柠檬酸脱氢酶1(IDH1)和α-地中海贫血/智力发育迟缓综合征X连锁基因(ATRX)在儿童胶质母细胞瘤中的表达及其临床和预后意义。
Childs Nerv Syst. 2019 Sep;35(9):1537-1545. doi: 10.1007/s00381-019-04222-z. Epub 2019 May 31.
2
Identification of novel long non-coding RNA in diffuse intrinsic pontine gliomas by expression profile analysis.通过表达谱分析鉴定弥漫性脑桥内生型胶质瘤中的新型长链非编码RNA
Oncol Lett. 2018 Nov;16(5):6401-6406. doi: 10.3892/ol.2018.9461. Epub 2018 Sep 19.
3
Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.
对流增强递送用于弥漫性脑桥内在型胶质瘤治疗
Curr Neuropharmacol. 2017;15(1):116-128. doi: 10.2174/1570159x14666160614093615.
4
B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.B7-H3,一个潜在的治疗靶点,在弥漫性内在脑桥神经胶质瘤中表达。
J Neurooncol. 2013 Feb;111(3):257-64. doi: 10.1007/s11060-012-1021-2. Epub 2012 Dec 12.
5
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.全基因组分析鉴定弥漫性内在脑桥神经胶质瘤中受体酪氨酸激酶和细胞周期调节基因的反复扩增。
J Clin Oncol. 2011 Oct 20;29(30):3999-4006. doi: 10.1200/JCO.2011.35.5677. Epub 2011 Sep 19.
6
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.脑干部位神经胶质瘤的基因和组织学精确模型中的放射治疗与培菲替尼的临床前评估。
Cancer Res. 2010 Mar 15;70(6):2548-57. doi: 10.1158/0008-5472.CAN-09-2503. Epub 2010 Mar 2.
7
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.MKRN1 E3 连接酶对 p53 和 p21 的差异调节控制细胞周期停滞和凋亡。
EMBO J. 2009 Jul 22;28(14):2100-13. doi: 10.1038/emboj.2009.164. Epub 2009 Jun 18.
8
Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.p53肿瘤抑制通路的优先失活以及表皮生长因子受体(EGFR)扩增的缺失,将原发性高级别儿童星形细胞瘤与原发性成人星形细胞瘤区分开来。
Brain Pathol. 2000 Apr;10(2):249-59. doi: 10.1111/j.1750-3639.2000.tb00258.x.
9
Establishment of two glioma cell lines from two surgical specimens obtained at different times from the same individual.
J Neurooncol. 1999 Feb;41(3):247-54. doi: 10.1023/a:1006172608019.
10
A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.胶质瘤细胞系中p16、p15、p53和p21基因改变的比较研究。
Jpn J Cancer Res. 1996 Sep;87(9):900-7. doi: 10.1111/j.1349-7006.1996.tb02118.x.